Allopurinol

證據等級: L5

預測適應症: 10 個

Allopurinol: From Gout / Hyperuricemia to Hepatic Porphyria

One-Sentence Summary

Allopurinol is a xanthine oxidase inhibitor classically used to treat gout and hyperuricemia by reducing uric acid production. The TxGNN model predicts it may be effective for Hepatic Porphyria, with 0 clinical trials and 2 publications currently offering only indirect mechanistic support for this direction.

Quick Overview

Item	Content
Original Indication	Gout / Hyperuricemia (known pharmacology; no Saudi Arabia registration on record)
Predicted New Indication	Hepatic Porphyria
TxGNN Prediction Score	99.95%
Evidence Level	L4
Saudi Arabia Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacology, allopurinol inhibits xanthine oxidase (XO), the enzyme responsible for the final two steps in uric acid synthesis from hypoxanthine and xanthine. By blocking XO, allopurinol reduces uric acid production and is established as first-line therapy for gout and hyperuricemia.

The proposed link to hepatic porphyria runs through a shared metabolic crossover between purine metabolism and heme biosynthesis. 5-Aminolevulinate synthase (ALAS) is the rate-limiting enzyme in hepatic heme synthesis and is subject to negative feedback by a small cytosolic heme pool. One hypothesis (PMID 31443750) proposes that metabolic targeting of ALAS activity — including via inhibitors that affect heme utilisation — could attenuate acute porphyric attacks. The xanthine oxidase pathway intersects with this at the level of reactive oxygen species (ROS): XO-generated ROS can deplete the heme regulatory pool or co-factors that modulate ALAS expression.

However, this mechanistic chain is highly indirect. Neither retrieved publication directly studies allopurinol in hepatic porphyria: one is a mechanistic hypothesis involving tryptophan 2,3-dioxygenase (TDO) inhibitors, and the other examines carbamazepine's porphyrogenic effects in rat liver — a drug with no structural or pharmacological overlap with allopurinol. The overall mechanistic connection is speculative and not supported by experimental data. An additional safety concern exists: allopurinol is associated with DRESS syndrome and drug-induced hepatitis, which poses meaningful risk in patients with already-compromised hepatic function, as is typical in porphyria.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31443750	2019	Hypothesis / Mechanistic Review	Medical Hypotheses	Proposes that metabolic inhibition of heme utilisation by tryptophan 2,3-dioxygenase (TDO) or use of tryptophan could target ALAS activity as a therapy for acute hepatic porphyrias; does not specifically study allopurinol
1567472	1992	Animal Study (rat liver)	Biochemical Pharmacology	Examines how carbamazepine exacerbates hepatic porphyria via heme pool depletion in rat liver; allopurinol is not studied; relevant only as contextual evidence for heme pathway perturbation

Safety Considerations

Please refer to the package insert for safety information.

Note from repurposing rationale: Allopurinol carries a known risk of DRESS syndrome and drug-induced hepatitis. For a target population with hepatic porphyria — where liver function is already compromised — this represents a material safety concern that must be characterised before any further development steps are considered.

Conclusion and Next Steps

Decision: Hold

Rationale: The sole evidence base is a TxGNN graph-embedding prediction (score 99.95%) supported only by two indirectly relevant publications at the mechanistic hypothesis level (L4); no clinical trials exist, and the mechanistic link between xanthine oxidase inhibition and hepatic porphyria is speculative. Compounding this, allopurinol's known hepatotoxicity and DRESS risk create a specific safety concern for this patient population that has not been characterised.

To proceed, the following is needed:

Confirm the mechanistic hypothesis in a validated in vitro or animal model of hepatic porphyria (e.g., measure effect of allopurinol on ALAS activity or heme pool in hepatocyte cultures)
Obtain allopurinol's full mechanism of action data from DrugBank (DG002 remediation) to enable a rigorous mechanistic-link assessment
Retrieve and review the package insert (DG001 remediation) to characterise hepatotoxicity and DRESS contraindications in the context of porphyria patients
Conduct a targeted literature search specifically for allopurinol + porphyria (current search returned 0 direct hits); consider searching for xanthine oxidase inhibitors as a class in porphyria models
If preclinical evidence is found, define a minimum safety monitoring plan for liver function and skin reactions before any human study is contemplated
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.